About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NVCR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301 · Metastatic Non-small Cell Lung Cancer
NovoTTF-200T, Pembrolizumab
NVCR
NovoCure GmbH
Phase 3Recruiting734Oct 2028Registry ↗
Nov 6, 2026EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newl…
NCT06556563 · Glioblastoma
Optune® device, Temozolomide
NVCR
NovoCure GmbH
Phase 3Active, not recruiting
was recruiting
741Apr 2029Registry ↗
Oct 5, 2026Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ…
NCT04471844 · Glioblastoma Multiforme
Optune®
NVCR
NovoCure Ltd.
Not applicableCompleted981Feb 19, 2026Registry ↗
Sep 4, 2026EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-P…
NCT06390059 · Metastatic Pancreatic Ductal Adenocarcinoma
Tumor Treating Fields, Atezolizumab
NVCR
NovoCure Ltd.
Phase 2Completed84Nov 18, 2025Registry ↗
Jun 1, 2026LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Tre…
NCT06558799 · Non-Small Cell Lung Cancer (NSCLC)
NovoTTF-200T, Pembrolizumab
NVCR
NovoCure GmbH
Phase 2Terminated31Feb 23, 2026Registry ↗
Mar 18, 2026Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for…
NCT02973789 · Nonsmall Cell Lung Cancer, NSCLC
NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
NVCR
NovoCure GmbH
Phase 3Completed291Sep 24, 2024Registry ↗
Jan 21, 2026Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pan…
NCT03377491 · Pancreas Adenocarcinoma
NovoTTF-200T, Gemcitabine
NVCR
NovoCure Ltd.
Phase 3Completed571Oct 16, 2024Registry ↗
Jan 6, 2026Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine a…
NCT07319910 · Locally Advanced Pancreatic Adenocarcinoma
TTFields, Gemcitabine
NVCR
NovoCure GmbH
—Temporarily not available——Registry ↗
Oct 31, 2025Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFiel…
NCT02831959 · Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
NovoTTF-200M device, Best Standard of Care
NVCR
NovoCure GmbH
Phase 3Completed298Nov 29, 2024Registry ↗
Aug 22, 2025TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
NCT05538806 · Pleural Mesothelioma
TTFields
NVCR
NovoCure Ltd.
—Recruiting198Dec 2027Registry ↗
Apr 23, 2025EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kH…
NCT04892472 · Non-small Cell Lung Cancer
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NVCR
NovoCure GmbH
Phase 2Terminated15Jan 10, 2025Registry ↗
Apr 11, 2025TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional S…
NCT06924099 · Glioblastoma
NVCR
NovoCure Ltd.
—Recruiting430Jan 31, 2029Registry ↗
Nov 14, 2024Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Tre…
NCT04281576 · Gastric Cancer, GastroEsophageal Cancer
NovoTTF-100L(P), Oxaliplatin
NVCR
NovoCure Ltd.
Not applicableCompleted28Jun 7, 2024Registry ↗
Nov 14, 2024Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatoce…
NCT03606590 · Hepatocellular Carcinoma
NovoTTF-100L(P) device, Sorafenib
NVCR
NovoCure Ltd.
Phase 2Completed25Jan 14, 2021Registry ↗
Aug 16, 2024Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurren…
NCT04492163 · Glioblastoma Multiforme
TTFields
NVCR
NovoCure GmbH
Phase 2Completed25Jun 20, 2023Registry ↗
Mar 29, 2024Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Trea…
NCT03940196 · Ovarian Cancer
NovoTTF-100L(O), Paclitaxel
NVCR
NovoCure Ltd.
Phase 3Completed540May 18, 2023Registry ↗
Jan 10, 2023TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study
NCT04717739 · Glioblastoma
TTFields
NVCR
NovoCure Ltd.
—Unknown500Dec 1, 2024Registry ↗
Jul 7, 2021Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the…
NCT04953234 · COVID-19
NovoTTF-100L
NVCR
NovoCure GmbH
Not applicableCompleted10Apr 26, 2021Registry ↗
Jan 28, 2021TTFields In GErmany in Routine Clinical Care
NCT03258021 · Glioblastoma
TTFields
NVCR
NovoCure Ltd.
—Unknown710Jun 2021Registry ↗
Dec 20, 2018TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
NCT03780569 · Glioblastoma Multiforme
NovoTTF-200A, Radiotherapy
NVCR
NovoCure Ltd.
Not applicableUnknown10Jan 2019Registry ↗
Sep 25, 2018Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin…
NCT02397928 · Malignant Pleural Mesothelioma
NovoTTF-100L device, Pemetrexed
NVCR
NovoCure Ltd.
Phase 2Completed82Apr 2018Registry ↗
Sep 13, 2017Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant Wit…
NCT01971281 · Pancreatic Adenocarcinoma
NovoTTF-100L, Gemcitabine
NVCR
NovoCure Ltd.
Phase 1/2Unknown40Dec 2017Registry ↗
Apr 10, 2017Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NCT00916409 · Glioblastoma Multiforme
NovoTTF-100A device, Temozolomide
NVCR
NovoCure Ltd.
Phase 3Completed700Dec 2016Registry ↗
Sep 21, 2016Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurren…
NCT02244502 · Ovarian Carcinoma
NovoTTF-100L(O), Paclitaxel
NVCR
NovoCure Ltd.
Phase 1/2Unknown31Dec 2016Registry ↗
Sep 21, 2016Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastase…
NCT01755624 · 1-5 Brain Metastases From Non-Small Cell Lung Cancer
NovoTTF-100A device, Best Standard of Care
NVCR
NovoCure Ltd.
Phase 2Unknown18Jul 2017Registry ↗
Mar 2, 2016Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
NCT01756729 · Recurrent Glioblastoma Multiforme
NovoTTF-100A
NVCR
NovoCure Ltd.
Phase 4Terminated13Jan 2018Registry ↗

26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 11:26 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances